Familial male-limited precocious puberty: Difference between revisions
Clarified; this is not a "traditional" autosomal dominant disease |
→External links: Too long to be a stub-see WP:STUB Tags: Mobile edit Mobile web edit |
||
| Line 60: | Line 60: | ||
[[Category:Rare diseases]] |
[[Category:Rare diseases]] |
||
[[Category:Cell surface receptor deficiencies]] |
[[Category:Cell surface receptor deficiencies]] |
||
{{genetic-disorder-stub}} |
|||
Revision as of 00:19, 2 October 2018
| Familial male-limited precocious puberty | |
|---|---|
 | |
| Male-limited precocious puberty has an autosomal dominant pattern of inheritance. However, only males are affected; females with the mutant gene are not affected. |
Familial male-limited precocious puberty, often abbreviated as FMPP, also known as familial sexual precocity or gonadotropin-independent testotoxicosis,[1] is a form of gonadotropin-independent precocious puberty in which boys experience early onset and progression of puberty.[2] Signs of puberty can develop as early as an age of 1 year.
The spinal length in boys may be short due to a rapid advance in epiphyseal maturation. It is an autosomal dominant[1] condition with a mutation of the luteinizing hormone (LH) receptor. Treatment is with drugs that suppress gonadal steroidogenesis, such as cyproterone acetate, ketoconazole, spironolactone, and testolactone.[3] Alternatively, the combination of the androgen receptor antagonist bicalutamide and the aromatase inhibitor anastrozole may be used.[4]
See also
- Follicle-stimulating hormone insensitivity
- Gonadotropin-releasing hormone insensitivity
- Hypergonadism, hyperandrogenism, and precocious puberty
- Inborn errors of steroid metabolism
- Leydig cell hypoplasia (or LH insensitivity)
References
- ^ a b Online Mendelian Inheritance in Man (OMIM): 176410
- ^ Traggiai C, Stanhope R (2003). "Disorders of pubertal development". Best Pract Res Clin Obstet Gynaecol. 17 (1): 41–56. doi:10.1053/ybeog.2003.0360. PMID 12758225.
- ^ Reiter EO, Norjavaara E (2005). "Testotoxicosis: current viewpoint". Pediatr Endocrinol Rev. 3 (2): 77–86. PMID 16361981.
- ^ Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z (Sep 2006). "Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole". The Journal of Pediatrics. 149 (3): 416–20. doi:10.1016/j.jpeds.2006.04.027. PMID 16939760.
External links
- Testotoxicosis at NIH's Office of Rare Diseases
This template is no longer used; please see Template:Endocrine pathology for a suitable replacement